Martin P Y
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
Praxis (Bern 1994). 1997 Jul 30;86(31-32):1194-7.
Sodium retention is the most common renal abnormality of cirrhosis and eventually leads to the formation of ascites. There is now a strong body of evidence that the arterial vasodilatation, mainly splanchnic, that occurs during liver cirrhosis is a major factor in the pathogenesis of renal sodium and water retention. The arterial vasodilatation and the subsequent hypotension stimulate a baroreceptor-mediated neurohormonal vasoconstrictor and antinatriuretic response in a attempt to compensate the relative underfilling of the circulation. The cause of the arterial vasodilatation is thought to be a circulating factor and several recent studies have implicated an excessive vascular production of nitric oxide (NO). In animal models of cirrhosis administration of NO antagonists corrects the hyperdynamic circulation and improves renal sodium excretion. The treatment of sodium retention is often difficult in liver cirrhosis and it is possible that the identification of a vasodilator substance which can be inhibited could provide a new tool in the therapeutic approach of sodium and water retention in cirrhosis.
钠潴留是肝硬化最常见的肾脏异常,最终会导致腹水形成。目前有大量有力证据表明,肝硬化期间发生的动脉血管扩张,主要是内脏血管扩张,是肾脏钠和水潴留发病机制中的一个主要因素。动脉血管扩张及随后出现的低血压会刺激压力感受器介导的神经激素血管收缩和利钠反应,试图补偿循环血量相对不足。动脉血管扩张的原因被认为是一种循环因子,最近的几项研究表明血管中一氧化氮(NO)生成过多。在肝硬化动物模型中,给予NO拮抗剂可纠正高动力循环并改善肾脏钠排泄。肝硬化患者的钠潴留治疗往往很困难,识别一种可被抑制的血管扩张物质可能为肝硬化钠和水潴留的治疗方法提供新工具。